Cargando…

Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review

Programmed cell death 1 (PD-1) blockade is considered contraindicated in liver transplant (LT) recipients due to potentially lethal consequences of graft rejection and loss. Though post-transplant PD-1 blockade had already been reported, pre-transplant use of PD-1 blockade has not been thoroughly in...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Zi-yun, Zhang, Zi-jie, Lv, Zi-cheng, Tong, Huan, Xi, Zhi-feng, Wu, Hao-xiang, Chen, Xiao-song, Xia, Lei, Feng, Hao, Zhang, Jian-jun, Xia, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326904/
https://www.ncbi.nlm.nih.gov/pubmed/34349755
http://dx.doi.org/10.3389/fimmu.2021.653437
_version_ 1783731944896331776
author Qiao, Zi-yun
Zhang, Zi-jie
Lv, Zi-cheng
Tong, Huan
Xi, Zhi-feng
Wu, Hao-xiang
Chen, Xiao-song
Xia, Lei
Feng, Hao
Zhang, Jian-jun
Xia, Qiang
author_facet Qiao, Zi-yun
Zhang, Zi-jie
Lv, Zi-cheng
Tong, Huan
Xi, Zhi-feng
Wu, Hao-xiang
Chen, Xiao-song
Xia, Lei
Feng, Hao
Zhang, Jian-jun
Xia, Qiang
author_sort Qiao, Zi-yun
collection PubMed
description Programmed cell death 1 (PD-1) blockade is considered contraindicated in liver transplant (LT) recipients due to potentially lethal consequences of graft rejection and loss. Though post-transplant PD-1 blockade had already been reported, pre-transplant use of PD-1 blockade has not been thoroughly investigated. This study explores the safety and efficacy of neoadjuvant PD-1 blockade in patients with hepatocellular carcinoma (HCC) after registration on the waiting list. Seven transplant recipients who underwent neoadjuvant PD-1 blockade combined with lenvatinib and subsequent LT were evaluated. The objective response rate (ORR) and disease control rate (DCR) was 71% and 85% according to the mRECIST criteria. Additionally, a literature review contained 29 patients were conducted to summarize the PD-1 blockade in LT for HCC. Twenty-two LT recipients used PD-1 inhibitors for recurrent HCC. 9.1% (2/22) and 4.5% (1/22) recipients achieved complete remission (CR) and partial remission (PR), respectively; 40.9% (9/22) recipients had progressive disease (PD). Allograft rejection occurred in 45% of patients. In total, seven patients from our center and three from the literature used pretransplant anti-PD-1 antibodies, eight patients (80%) had a PR, and the disease control rate was 100%. Biopsy-proven acute rejection (BPAR) incidence was 30% (3 in 10 patients), two patients died because of BPAR. This indicated that neoadjuvant PD-1-targeted immunotherapy plus tyrosine kinase inhibitors (TKI) exhibited promising efficacy with tolerable mortality in transplant recipients under close clinical monitoring.
format Online
Article
Text
id pubmed-8326904
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83269042021-08-03 Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review Qiao, Zi-yun Zhang, Zi-jie Lv, Zi-cheng Tong, Huan Xi, Zhi-feng Wu, Hao-xiang Chen, Xiao-song Xia, Lei Feng, Hao Zhang, Jian-jun Xia, Qiang Front Immunol Immunology Programmed cell death 1 (PD-1) blockade is considered contraindicated in liver transplant (LT) recipients due to potentially lethal consequences of graft rejection and loss. Though post-transplant PD-1 blockade had already been reported, pre-transplant use of PD-1 blockade has not been thoroughly investigated. This study explores the safety and efficacy of neoadjuvant PD-1 blockade in patients with hepatocellular carcinoma (HCC) after registration on the waiting list. Seven transplant recipients who underwent neoadjuvant PD-1 blockade combined with lenvatinib and subsequent LT were evaluated. The objective response rate (ORR) and disease control rate (DCR) was 71% and 85% according to the mRECIST criteria. Additionally, a literature review contained 29 patients were conducted to summarize the PD-1 blockade in LT for HCC. Twenty-two LT recipients used PD-1 inhibitors for recurrent HCC. 9.1% (2/22) and 4.5% (1/22) recipients achieved complete remission (CR) and partial remission (PR), respectively; 40.9% (9/22) recipients had progressive disease (PD). Allograft rejection occurred in 45% of patients. In total, seven patients from our center and three from the literature used pretransplant anti-PD-1 antibodies, eight patients (80%) had a PR, and the disease control rate was 100%. Biopsy-proven acute rejection (BPAR) incidence was 30% (3 in 10 patients), two patients died because of BPAR. This indicated that neoadjuvant PD-1-targeted immunotherapy plus tyrosine kinase inhibitors (TKI) exhibited promising efficacy with tolerable mortality in transplant recipients under close clinical monitoring. Frontiers Media S.A. 2021-07-19 /pmc/articles/PMC8326904/ /pubmed/34349755 http://dx.doi.org/10.3389/fimmu.2021.653437 Text en Copyright © 2021 Qiao, Zhang, Lv, Tong, Xi, Wu, Chen, Xia, Feng, Zhang and Xia https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Qiao, Zi-yun
Zhang, Zi-jie
Lv, Zi-cheng
Tong, Huan
Xi, Zhi-feng
Wu, Hao-xiang
Chen, Xiao-song
Xia, Lei
Feng, Hao
Zhang, Jian-jun
Xia, Qiang
Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review
title Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review
title_full Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review
title_fullStr Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review
title_full_unstemmed Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review
title_short Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review
title_sort neoadjuvant programmed cell death 1 (pd-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326904/
https://www.ncbi.nlm.nih.gov/pubmed/34349755
http://dx.doi.org/10.3389/fimmu.2021.653437
work_keys_str_mv AT qiaoziyun neoadjuvantprogrammedcelldeath1pd1inhibitortreatmentinpatientswithhepatocellularcarcinomabeforelivertransplantacohortstudyandliteraturereview
AT zhangzijie neoadjuvantprogrammedcelldeath1pd1inhibitortreatmentinpatientswithhepatocellularcarcinomabeforelivertransplantacohortstudyandliteraturereview
AT lvzicheng neoadjuvantprogrammedcelldeath1pd1inhibitortreatmentinpatientswithhepatocellularcarcinomabeforelivertransplantacohortstudyandliteraturereview
AT tonghuan neoadjuvantprogrammedcelldeath1pd1inhibitortreatmentinpatientswithhepatocellularcarcinomabeforelivertransplantacohortstudyandliteraturereview
AT xizhifeng neoadjuvantprogrammedcelldeath1pd1inhibitortreatmentinpatientswithhepatocellularcarcinomabeforelivertransplantacohortstudyandliteraturereview
AT wuhaoxiang neoadjuvantprogrammedcelldeath1pd1inhibitortreatmentinpatientswithhepatocellularcarcinomabeforelivertransplantacohortstudyandliteraturereview
AT chenxiaosong neoadjuvantprogrammedcelldeath1pd1inhibitortreatmentinpatientswithhepatocellularcarcinomabeforelivertransplantacohortstudyandliteraturereview
AT xialei neoadjuvantprogrammedcelldeath1pd1inhibitortreatmentinpatientswithhepatocellularcarcinomabeforelivertransplantacohortstudyandliteraturereview
AT fenghao neoadjuvantprogrammedcelldeath1pd1inhibitortreatmentinpatientswithhepatocellularcarcinomabeforelivertransplantacohortstudyandliteraturereview
AT zhangjianjun neoadjuvantprogrammedcelldeath1pd1inhibitortreatmentinpatientswithhepatocellularcarcinomabeforelivertransplantacohortstudyandliteraturereview
AT xiaqiang neoadjuvantprogrammedcelldeath1pd1inhibitortreatmentinpatientswithhepatocellularcarcinomabeforelivertransplantacohortstudyandliteraturereview